GlaxoSmithKline (GSK) and clinical-stage biopharma company Mersana Therapeutics have forged a global collaboration, giving GSK the exclusive option to codevelop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056 targeting HER2.
Source: Drug Industry Daily